UCLA Health Melanoma Program, Los Angeles, CA.
Semin Oncol Nurs. 2021 Apr;37(2):151131. doi: 10.1016/j.soncn.2021.151131. Epub 2021 Mar 28.
It is an exciting time in oncology nursing as new treatments are continually emerging to improve oncological outcomes for people affected by cancer. Immunotherapy is one such innovation in contemporary oncology practice, but the side effects of its treatment can be life threatening. Oncology nurses must be educated in the early identification of life-threatening side effects, and deliver evidence-based interventions to manage consequences of therapy such as, immune checkpoint inhibitor-related adrenal insufficiency.
This article utilizes a case study to emphasize the need for early identification and interventions for clinical management of immunotherapy related adrenal insufficiency. A review of the current evidence is included to provide recommendations for oncology nurses who are involved in providing care for people affected by cancer receiving immunotherapy.
Oncology nurses are the frontline caregivers to assess, recognize, so that early intervention and treament can lead to optimal patient outcomes.
Adrenal insufficiency is a life-threatening condition that is difficult to diagnose but if recognized early, morbidity can be prevented, quality of life improved, treatment initiated and life saving immunotherapy treatment can safely continue. Oncology nurses play an active role in ensuring the safe administration of immunotherapy by recognizing this important immune related adverse event. I would like to give credit to Patricia Jakel, RN, MSN, UCLA CNS and Dr. Melissa Lechner, UCLA endocrinologist for their invaluable input in this article.
肿瘤护理学正处于令人兴奋的时期，因为新的治疗方法不断涌现，以改善癌症患者的肿瘤学治疗效果。免疫疗法是当代肿瘤学实践中的一项创新，但它的治疗副作用可能危及生命。肿瘤护士必须接受早期识别危及生命的副作用的教育，并提供循证干预措施来管理治疗的后果，如免疫检查点抑制剂相关的肾上腺功能不全。
本文利用病例研究强调了早期识别和干预免疫治疗相关肾上腺功能不全的临床管理的必要性。对现有证据进行了回顾，为参与为接受免疫治疗的癌症患者提供护理的肿瘤护士提供了建议。
肿瘤护士是评估和识别的第一线护理人员，以便早期干预和治疗可以带来最佳的患者结局。
肾上腺功能不全是一种危及生命的疾病，难以诊断，但如果及早发现，可以预防发病，提高生活质量，启动治疗并安全地继续进行挽救生命的免疫治疗。肿瘤护士通过识别这种重要的免疫相关不良事件，在确保免疫疗法的安全管理方面发挥着积极的作用。我要感谢 UCLA CNS 的 Patricia Jakel，RN，MSN 和 UCLA 内分泌学家 Melissa Lechner 博士在本文中的宝贵意见。
